IDXX

AI Research

IDEXX CEO Sells $15.3M in Stock → Leadership Transition May 2026, FY2026 EPS $14.29-14.80

IDEXX Laboratories disclosed CEO stock sales totaling $15.3 million ahead of a planned leadership transition scheduled for May 2026, creating uncertainty around company direction despite solid FY2026 EPS guidance of $14.29-14.80. Analysts maintain a Buy consensus with an average price target of $800.00, reflecting long-term confidence in IDEXX's dominant position in companion animal veterinary diagnostics and the structural growth of the pet healthcare market. Risks include the leadership transition execution risk, potential deceleration in veterinary clinic visits if pet owners face economic pressure, and intensifying point-of-care diagnostics competition.